First-line panitumumab plus docetaxel and cisplatin in advanced gastric and gastro-oesophageal junction adenocarcinoma: results of a phase II trial.

Guillermo Quintero-AldanaM SalgadoS CandamioJ C MéndezM JorgeM ReboredoL Vázquez TuñasC RomeroM CovelaA Fernández MontesM CarmonaY Vidal InsuaR Lópeznull null

Published in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2019)

The addition of panitumumab to standard chemotherapy as the first-line treatment in advanced gastric or GEJ-ADC does not appear to improve the efficacy outcomes.

Keyphrases

locally advanced
wild type
metastatic colorectal cancer
squamous cell carcinoma
open label
magnetic resonance imaging
diffusion weighted
skeletal muscle
adipose tissue
study protocol
glycemic control